gdc

Colorectal Cancer

No Evidence of Disease, or NED: How Is It Going for You?
SurvivorshipColorectal Cancer
August 2022 Vol 8 No 4 – August 17, 2022
Joe Bullock finally heard the 3 little letters he’d been waiting to hear since his colorectal cancer diagnosis: NED. But he wasn’t expecting the uncertainty that shortly followed, feeling stuck in the in-between phase “after cancer.”
Drugs for Colorectal Cancer
Colorectal Cancer
Find financial assistance programs available for colorectal cancer drugs.
What It Really Means to “Man Up”
Colorectal CancerMen's HealthSurvivorship
December 2021 Vol 7 No 6 – December 22, 2021
Six months before he was diagnosed with stage IIIB colorectal cancer, both of Joe Bullock’s parents passed away. Chemotherapy hit him hard and stirred a mixture of depression and feelings of inadequacy as a husband and father. Then he discovered the power of opening up.
First-Line Treatment with Keytruda Doubles the Time without Disease Progression in Patients with MSI-H or dMMR Metastatic Colorectal Cancer
Colorectal Cancer
ASCO 2020 Highlights – September 8, 2020
New study results presented at the 2020 ASCO annual meeting suggest that there is a new standard of care for the first-line treatment of some patients with advanced colorectal cancer. This was the first study to compare the use of Keytruda (pembrolizumab), a PD-1 inhibitor, versus chemotherapy to see which is the best first treatment for patients with metastatic (spreading) colorectal cancer and microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) abnormalities.
Opdivo plus Yervoy May Be New First-Line Option for Patients with MSI-H or dMMR Colorectal Cancer
Colorectal Cancer
ASCO 2020 Highlights – September 8, 2020
The use of first-line immunotherapy combination with Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) continues to show robust, long-term benefit in patients with microsatellite instability high (MSI-H) or with mismatch repair-deficient (dMMR) metastatic (spreading) colorectal cancer, according to new study results presented at the 2020 ASCO annual meeting.
First-Line Immunotherapy New Standard of Care in Some Patients with Metastatic Colorectal Cancer
Colorectal CancerImmunotherapy
August 2020 – Immunotherapy – August 26, 2020
A new study was presented at the 2020 ASCO meeting that compared, for the first time, the use of immunotherapy versus chemotherapy for treating patients with metastatic colorectal cancer and microsatellite instability-high or mismatch repair-deficient abnormalities.
Learning I Had Lynch Syndrome Helped Save My Life
Colorectal CancerGenetics & CancerPatient Stories
June 2020 Vol 6 No 3 – June 24, 2020
Lynch syndrome is a hereditary genetic abnormality that can cause several types of cancer. Wenora Johnson discovered that it ran in her family after she had treatment for colon cancer. Knowing that she was at a high risk for certain cancers, and having 2 children already, she had her ovaries and uterus removed, as prevention.
Healthy Food Habits for Colon Cancer Risk Reduction and Survivorship
Nutrition & CancerColorectal Cancer
February 2020 Vol 6 No 1 – February 21, 2020
Oncology dietitian Julie Lanford offers tips on how to reduce the risk of colon cancer, as well as strategies for survivors during and after cancer treatment.
Recovering from Survivor Guilt After Surviving Hurricane Katrina and Colorectal Cancer
Colorectal CancerPatient Stories
August 2019 Vol 5 No 4 – August 27, 2019
As a psychologist dedicated to helping people cope with disasters, Jamie D. Aten knew the damage “survivor’s guilt” can do. As a stage IV colon cancer survivor, he says, “I wasn’t prepared for it to hit me personally.”
Gift of the Dragonflies
Colorectal CancerPatient Stories
When treatment for advanced colon cancer forced Cindy Simpson Wise to slow her busy pace, she found comfort in surrounding herself with nature’s beauty and in focusing on hope and joy.
Page 1 of 3
Results 1 - 10 of 24

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests